Clinical trials: Suspected Prostate Cancer, open to volunteers
Suspected Prostate Cancer (increased PSA Level)
Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI)
Prostate cancer is the second most common type of cancer in men only after lung cancer, and accounts for ~3.8% of all deaths caused in men in 2018.
- Trial name
- ProstaCEST (NCT06669273)
- Testing
- CEST MRI sequence at 3T
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Clermont-Ferrand
Suspected Prostate Cancer
MRI Guided Prostate Biopsy
This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy.
- Trial name
- NCT06302595
- Testing
- MRI-guided prostate biopsy using the needle holder frame.
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Brigham and Women's Hospital
Treatment-naive Prostate Cancer, Suspected Prostate Cancer
Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer
Brief Summary This prospective, multicenter study evaluates whether delayed PSMA PET imaging improves diagnostic efficacy for detecting clinically significant prostate cancer (Gleason score ≥7) compared with standard imaging in…
- Conditions
- Treatment-naive Prostate Cancer, Suspected Prostate Cancer, Molecular Imaging
- Trial name
- DEPICT (NCT07531329)
- Testing
- [⁶⁸Ga]Ga-PSMA PET/CT with Delayed Pelvic PET-Only Acquisition
- Where
- 9 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Xijing Hospital
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Prostate Cancer
Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer
Thousands of men take a PSA test to investigate whether they have prostate cancer every year. For the vast majority, the test is normal and further investigations are not necessary.
- Trial name
- PRORAND (NCT07422597)
- Testing
- European Study of screening for prostate cancer risk calculator
- Where
- 3 sites in Norway
- Volunteers
- 1,016 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Prostate Cancer
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
This study evaluates the diagnostic performance and safety of 68Ga-NYM032 PET/CT imaging in patients with suspected recurrence of prostate cancer.
- Trial name
- NCT07649122
- Testing
- 68-Ga-NYM032
- Where
- 2 sites in China
- Volunteers
- 232 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostate Cancer Recurrent
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in participants with suspected recurrent prostate cancer after radical treatment.
- Trial name
- NCT06922929
- Testing
- INR101
- Where
- 32 sites in China
- Volunteers
- 110 people
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd